Artemether + Lumefantrine Tablet Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 20 mg/120 mg per tablet
Reference Brands: Coartem(EU)
Category:
Medical Aid
Artemether–Lumefantrine inhibits Plasmodium falciparum by disrupting parasite DNA and calcium homeostasis, leading to parasite death. It effectively treats uncomplicated malaria, offering rapid symptom relief, high cure rates, and convenient oral dosing. Its combination prevents resistance development, making it a preferred first-line therapy in endemic regions.
Artemether + Lumefantrine tablet is available in Tablet
and strengths such as 20 mg/120 mg per tablet.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Artemether + Lumefantrine tablet is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Artemether + Lumefantrine tablet can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Artemether + Lumefantrine tablets, marketed as Coartem, are approved in some EU countries for uncomplicated Plasmodium falciparum malaria. In the EU, brands are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards, though approval status varies. In the US, the combination is not approved for malaria treatment, but importation for travel use is permitted. Both regions require detailed dossiers, clinical trial data, quality assurance, and pharmacovigilance plans for approval and ongoing safety monitoring. For expert regulatory support, dossier preparation, and compliance, visit PharmaTradz. We facilitate seamless market access, ensuring adherence to European and US standards for safe, effective malaria therapy.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing